Johnson & Johnson (JNJ) Holdings Held by Chase Investment Counsel Corp
Chase Investment Counsel Corp continued to hold its position in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,605 shares of the company’s stock at the end of the second quarter. Chase Investment Counsel Corp’s holdings in Johnson & Johnson were worth $476,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also made changes to their positions in the company. State Street Corp lifted its stake in shares of Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Johnson & Johnson by 3.7% in the second quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock valued at $1,521,258,000 after purchasing an additional 405,517 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Johnson & Johnson by 1.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock valued at $1,388,775,000 after purchasing an additional 201,703 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in Johnson & Johnson by 3.4% in the first quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock valued at $1,188,684,000 after purchasing an additional 310,831 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Johnson & Johnson by 0.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock valued at $990,041,000 after purchasing an additional 42,144 shares during the last quarter. Institutional investors own 65.90% of the company’s stock.
Shares of Johnson & Johnson (NYSE JNJ) traded up 0.58% on Wednesday, reaching $132.87. The company had a trading volume of 1,767,653 shares. The firm has a market capitalization of $356.62 billion, a PE ratio of 22.48 and a beta of 0.78. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The company’s 50-day moving average is $132.27 and its 200 day moving average is $129.78.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.74 earnings per share. Equities analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is 56.76%.
JNJ has been the subject of a number of recent analyst reports. Cowen and Company restated an “outperform” rating and set a $143.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, June 13th. Royal Bank Of Canada restated a “buy” rating and set a $128.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 15th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $140.00 target price on shares of Johnson & Johnson in a research report on Friday, June 16th. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Finally, Morgan Stanley increased their target price on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. Five investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and an average price target of $134.79.
In other news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.